Lilly and Boehringer rejig diabetes alliance as Jardiance so...

Eli Lilly and Boehringer Ingelheim have changed the terms of their diabetes alliance to focus their energies on developing their big-selling Jardiance pill.

Novartis’ Cosentyx didn’t EXCEED Humira in psoriatic arthrit...

Lilly's new drugs offset slumping sales of erectile dysfunct...

Eli Lilly upped its guidance for 2019 after posting strong third quarter results, as more recently released drugs offset sales lost as former erectile dysfunction blockbuster Cialis lost pa

CHMP backs Lilly’s Baqsimi as non-injectable for severe low ...

Lilly's $1.6bn cancer drug draws blank in pancreatic cancer ...

Eli Lilly is looking at other uses for its new cancer immunotherapy pegilodecakin after it flopped in a phase 3 pancreatic cancer trial.

FDA approves Lilly's new migraine attack drug, rival from Al...

The FDA has approved Eli Lilly’s new migraine drug lasmiditan, offering patients a new option to relieve symptoms should they feel an attack coming on.